Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Onsdag 15 Januari | 07:57:07 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Cantargia Q2 2024 - CAN10 Proof-of-Mechanism

Prenumeration

Cantargia Q2 2024 - CAN10 Proof-of-Mechanism

2024-08-29 08:15:00

Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Redeye

Bifogade filer

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden